Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection

References

• Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243–253.
   PubMed Web of Science ®Google Scholar
• He M, Qin H, Poon TC, et al. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs. Carcinogenesis. 2015;36(9):1008–1018.
   PubMed Web of Science ®Google Scholar
• Zheng R, Zeng H, Zhang S, et al. National estimates of cancer prevalence in China, 2011. Cancer Lett. 2016;370(1):33–38.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576.
   PubMed Web of Science ®Google Scholar
• Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med. 2011;6(1):93–98.
   PubMedGoogle Scholar
• Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429–2438.
   PubMed Web of Science ®Google Scholar
• Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35–43.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997;182(3):318–324.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853.
   PubMed Web of Science ®Google Scholar
• Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–855.
   PubMed Web of Science ®Google Scholar
• Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287.
   PubMed Web of Science ®Google Scholar
• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388(10049):1081–1088.
   PubMed Web of Science ®Google Scholar
• Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1):S84–S101.
   PubMed Web of Science ®Google Scholar
• Goto T, Yoshida H, Tateishi R, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011;5(3):767–773.
   PubMed Web of Science ®Google Scholar
• Estevez J, Chen VL, Podlaha O, et al. Differential serum cytokine profiles in patients with chronic hepatitis B, C, and hepatocellular carcinoma. Sci Rep. 2017;7(1):11867.
   PubMedGoogle Scholar
• Garcia-Knight MA, Nduati E, Hassan AS, et al. Altered memory T-cell responses to bacillus Calmette-Guerin and tetanus toxoid vaccination and altered cytokine responses to polyclonal stimulation in HIV-Exposed uninfected Kenyan infants. PLoS One. 2015;10(11):e0143043.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Kitamura H, Takahashi N, et al. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells. Cancer Immunol Immunother. 2016;65(2):193–204.
   PubMed Web of Science ®Google Scholar
• Narita Y, Kitamura H, Wakita D, et al. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol. 2013;190(2):812–820.
   PubMed Web of Science ®Google Scholar
• Pan QZ, Pan K, Wang QJ, et al. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Stem Cells. 2015;33(2):354–366.
   PubMed Web of Science ®Google Scholar
• Cheng L, Du X, Wang Z, et al. Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol. 2014;61(6):1297–1303.
   PubMed Web of Science ®Google Scholar